Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC has repurchased 8,444,107 of its own ordinary shares for cancellation as part of a share buyback programme launched in March 2026, with purchases executed across venues including the London Stock Exchange and Cboe UK between 20 and 24 April at volume-weighted average prices largely in the mid-350 pence range. Following these transactions, Haleon’s registered share capital stands at 8,902,639,582 ordinary shares, of which 12,281,053 are held in treasury, leaving 8,890,358,529 shares with voting rights, a change that may affect investors’ disclosure thresholds and underscores the company’s ongoing capital management efforts.
The revised share count clarifies the base for calculating voting power and regulatory disclosure requirements, giving shareholders updated visibility on their ownership stakes. The buyback, which reduces the number of shares in issue, is likely to enhance earnings per share over time and signals management’s confidence in the business, while also tightening the free float for investors in the consumer health specialist.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.15 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon PLC is a consumer healthcare company focused on improving everyday health, with a portfolio spanning oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin care. Its well-known brands, including Sensodyne, Panadol, Advil, Voltaren and Centrum, reach more than a billion consumers worldwide and are widely recommended by health professionals.
Average Trading Volume: 21,529,561
Technical Sentiment Signal: Sell
Current Market Cap: £31.6B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.